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Vaginal use of micronized progesterone for luteal support.
A randomized study comparing Utrogestan® and Crinone® 8%
Lucie Michnovaa, Jiri Dostalb, Milan Kudelab,c, Petr Hamald, Katerina Langovae
Background and Objective. Luteal phase physiology is distorted by in vitro fertilization (IVF) cycles using gonado-
tropin-releasing hormone (GnRH) agonists and antagonists, Controlled ovarian hyperstimulation leads to luteal phase 
defect and for this reason, luteal phase support is now an integral part of IVF/ICSI-ET programs. The support is provided 
by hCG, progesterone or GnRH-a. This study compared the efficiency, safety and tolerance of two vaginal micronized 
progesterones, Utrogestan and Crinone 8%. 
Methods. 111 women, 18-40 years old, FSH < 10 IU/L and normal uterus findings were included. The efficiency of the 
two preparations to provide luteal support was evaluated by the fertilization, implantation, pregnancy and take-home 
baby rates. The safety was compared through the results of vaginal findings and vaginal inflammation markers before 
and after treatment. Comparison of tolerance was made by evaluating 21 subjective patient questionnaire parameters. 
Results. There were no significant differences between the preparations in terms of efficiency or safety though Crinone 
8% was better tolerated.
Conclusion. The outcomes of this study suggest that a vaginal gel with micronized progesterone (Crinone 8%) is the 
optimal choice at this time for luteal support.
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INTRODUCTION
According to the Czech National Registry of 
Reproduction Health and the National Registry of Assisted 
Reproduction (NRAR), the need for assisted reproduc-
tion techniques (ART) is increasing. The main methods 
used are in vitro fertilization (IVF) and intracytoplasmic 
sperm injections (ICSI). There were 32245 cycles of as-
sisted reproduction in the Czech Republic in 2013 (ref.1). 
In Belgium, Denmark, Estonia, Iceland, Norway, Slovenia, 
Sweden and the Czech Republic more than 3.0% of all 
newborns are conceived by assisted reproduction. It is es-
timated that there are 1.5 million cycles of AR around 
the world and 350 000 children are born by this method 
every year2. 
From the foregoing, it is thus crucial to have an op-
timally prepared endometrium for successful implanta-
tion of the embryo. The process starts in the proliferative 
phase of the menstrual cycle and continues into the luteal 
phase. For proper growth of the endometrium, the two 
basic hormones are estradiol (E) and progesterone (P). 
In the follicular phase of the natural cycle, the follicle 
stimulating hormone (FSH) stimulates the granulous cells 
of the Graafian follicle to produce E. Its level gradually 
increases and reaches a peak just before a steep rise in 
luteinizing hormone (LH). This triggers the ovulation pro-
cess. After ovulation, the collapsed follicle and residual 
granulous cells form the corpus luteum. Steroid produc-
tion depends on increasing levels of LH during the luteal 
phase3,4. The secretion of E and P culminates four days 
after ovulation. This then continues for about a week and 
decreases four days before the next period. 
Both hormones are responsible for the proper growth 
and transformation of the endometrium4. The endome-
trium is the main target tissue of sex hormones and pro-
gesterone is responsible for the secretory transformation 
of the endometrium primed by estrogen. P affects local 
vasodilatation and decreases the contractility of the myo-
metrium. The endometrial cycle depends on the ovarian 
cycle and corresponds to its two phases divided by ovula-
tion. Hence the main role in the maturation of the endo-
metrium, implantation of the embryo and conservation 
of the pregnancy depends on an optimal ratio of E to P 
(ref.5). During the secretory phase of the endometrium, 
there is a relatively short period for viable implantation, 
the so called implantation window6,7. 
After the impregnation, the production of P continues, 
due to the stimulation of the corpus luteum by human 
chorionic gonadotrophin (hCG) (ref.8). An adequate lu-
teal function is therefore necessary not only for successful 
implantation of the embryo but also for maintenance of 
the pregnancy. The production of steroids by the corpus 
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luteum starts in the 5th week. It is then gradually taken 
over by the placenta9. The placenta is the only source of 
P and E after the 7th week of pregnancy10.
Since the start of ART it is obvious that the luteal 
phase is insufficient in AR. One theory postulated that 
oocytes retrieval itself is responsible for luteal phase in-
sufficiency and hence for insufficient steroid production. 
Later it was confirmed that the retrieval of only one fol-
licle does not impair the luteal phase11. The luteal phase 
in stimulated cycles is different from the luteal phase in 
a natural cycle. It has been confirmed that the multifol-
licular development itself has an effect on the length of 
the luteal phase12. Stimulation after oocyte retrieval leads 
to the development of multiple corpora lutea and hence 
the levels of E and P are supraphysiological in the early 
luteal phase. The relative hyperestrinism suppresses hy-
pophysal LH production and it is believed that this is 
possible trigger mechanism of premature luteolysis13. The 
mechanism of premature luteolysis is not known in detail 
but the studies point to an indirect influence of E on the 
corpus luteum14,15. The length of ovarian steroid produc-
tion after controlled ovarian hyperstimulation (COH) is 
about two or three days shorter than in the natural cycles4. 
Premature decrease in ovarian steroid production was the 
reason for the introduction of luteal support into IVF/
ET cycles16,17. Gonadotrophin-releasing hormone ago-
nists (GnRH-a) and gonadotrophin-releasing hormone 
antagonists (GnRH-ant.) used in stimulation protocols 
emphasised the problem of a short luteal phase. For this 
reason, luteal support is a standard part of the treatment 
in IVF/ET programs18.
The most important factor of sufficient production of 
endogenous P in stimulated cycles is hCG. After induct-
ing oocytes maturation by exogenous hCG, the corpora 
lutea survive under its influence up to the 6th day. Rapid 
decrease in P levels then ensues19. In case of an impregna-
tion after the ET on the 8th day, the level of endogenous 
hCG rises again and the corpora lutea are stimulated for 
production of P (ref.18). There is thus a 3 day interval 
of progesterone insufficiency and luteal support then be-
came a fundamental part of the IVF/ICSI-ET program. 
This can be provided two ways. P can be delivered exog-
enously or corpus luteum can be stimulated to produce 
its own P after the retrieval of oocytes. Progesterone is 
routinely used for luteal support. It is possible to deliver 
progesterone orally, intramuscularly, subcutaneously and 
via the vagina, rectum, nose. The usual routes are oral, 
intramuscular and vaginal. 
The development of the micronized technique pro-
vided better absorption of the delivered progesterone. 
Micronized progesterone is clear gestagen and very com-
patible with natural progesterone. It acts on progesterone 
receptors and has no androgenicity.
The target of this study was to compare the efficiency, 
safety and tolerance of the vaginal use of micronized P 
for luteal support. The women in the first group were 
given Utrogestan and in the second group, Crinone 8%. 
We also studied changes in vaginal microflora and signs 
of vaginal inflammation.
PATIENTS AND METHODS
Entry criteria and ethical aspects
The study took place in The Centre of Assisted 
Reproduction, University Hospital in Olomouc. Entry 
criteria for participation were: age 18-40years, basic value 
of FSH less than 10 IU/L, normal finding in the uterine 
cavity proven by hysterosalpingography or hysteroscopy. 
According to the statistical power analysis it was nec-
essary to randomize minimally 51 patients in each group 
to confirm a 15% difference in the efficiency, safety and 
tolerance between groups. It was expected that 16% of 
patients will not finish the study after the randomization. 
111 patients who underwent controlled ovarian stimula-
tion within the IVF/ICSI/ET program were included 
in the study. All patients fulfilled inclusion criteria and 
signed an informed consent approved by the Ethics board. 
To rule out patients with low ovarian response, the crite-
ria for participation in the study were: E level more than 
1000 pg/mL (3671 pmol/L) on the day of hCG adminis-
tration and less than 5000 pg/mL (18355 pmol/L) due 
to increased risk of hyperstimulation syndrome OHSS.
There were 58 patients in the Utrogestan group and 
53 patients in the Crinone 8% one. The patients were 
prospectively randomized to one of the two arms of the 
study according to a PC generated program.
Controlled Ovarian Hyperstimulation (COH)
We used a long depot follicular protocol for controlled 
ovarian hyperstimulation with GnRH-a/rFSH (gonado-
trophin- releasing hormone agonist/recombinant FSH) 
(Zoladex, Decapeptyl, Diphereline/Gonal F, Puregon). 
HCG was administered when the biggest follicle reached a 
diameter of 20 mm and oocyte retrieval was carried out. The 
embryo transfer was done after 3 days of embryo cultivation.
Luteal support
On the day of oocyte retrieval, E levels were evaluated 
and the patients were randomized to the groups The pa-
tients in the first group were on Utrogestan (600 mg) - 2 
capsules 3 times a day vaginally, patients in the second 
group on Crinone 8% (90 mg), one dose of vaginal gel 
daily. The micronized progesterone medication started 2 
days after the oocyte retrieval and in case of positive hCG, 
continued up to the 10th week of pregnancy.
Vaginal microscopy and cultivation
The cultivation and microscopic examination of the 
vaginal smear was carried out on the day of positive hCG 
test. The same day, patients answered the questionnaires. 
Microbiological findings were assessed by a microbiologist. 
Outcomes
The evaluation criteria were: fertilization rate (FR), im-
plantation rate (IR), pregnancy rate (PR), take home baby 
rate (THBR), number of cryopreserved embryos, abor-
tion rate, pregnancies after 12th week of pregnancy, OHSS, 
mode of delivery, duration of pregnancy, baby weight, mul-
tiple pregnancies, gender of babies. Further comparison 
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criteria were: safety, changes in vaginal microflora, signs of 
vaginal inflammation, evaluation of tolerance by question-
naires. Patients responded on a scale of 1 - 4 (no problems, 
slight, moderate, severe). Questions were focused on the 
route of administration, vaginal irritation, escape of medi-
cation from the vagina, sickness, vomiting, discomfort, 
constipation, diarrhoea, stomach-ache, headache, breast 
tension, joint ache, genital itching, somnolence, feeling of 
increased discharge, irritation of external genitals caused 
by discharge, feeling of urinary frequency (day and night), 
decreased sexual desire, dyspareunia.
Statistical analysis 
The data are presented as median, minimal- maximal 
value, average and standard deviation. The data were rated 
through Shapiro-Wilks tests of normality. Given a skewed 
distribution, the means/medians were compared using a 
Mann-Whitney U-test. All tests were done on the level 
P<0.05 statistical significance. The IBM SPSS Statistics 
22 program was used.
The patients were also compared by age. The ages were 
compared using a t-test.
RESULTS
Infertility duration, infertility factor, number of previ-
ous IVF cycles, ICSI, AH, OHSS and spontaneous abor-
tions are shown in Table 1.
Table 1. Demographic and treatment data for patients using Utrogestan and Crinone 8%. 
Parameter Utrogestan Crinone 8% P
Number of patients 58 53  
Age 31.7 ± 3.5 30.8 ± 3.2 0.145
Infertility (years) 4.0 ± 3.1 4.1 ± 2.9 0.538
Ovarian factor 7/58 (12.10%) 5/53 (9.40%) 0.848
Tubal factor 21/58 (36.2%) 17/53 (32.1%)
Male factor 22/58 (37.9%) 25/53 (47.2%)
Endometriosis 4/58 (6.9%) 4/53 (7.5%)
Another factors 4/58 (6.9%) 2/53 (3.8%)
Basic FSH 6.4±1.8 6.6±1.6 0.658
Number of previous IVF/ET- 0 cycles 42/58 (72.4%) 35/53 (66.0%) 0.722
Number of previous IVF/ET- 1 cycles 11/58 (19.0%) 13/53 (24.5%)
Number of previous IVF/ET- 2 cycles 4/58 (6.9%) 5/53 (9.4%)
Number of previous IVF/ET- 3 cycles 1/58 (1.7%) 0/53 (0.0%)
FSH for stimulation (IU) 2265±1179 1978±451 0.138
Estradiol on the day of hCG administration (pmol/L) 10889±3645 11246±3383 0.71
Progesterone on the day of hCG administration (nmol/L) 2.7±1.5 2.6±1.5 0.732
Estradiol on the day of oocytes retrieval (pmol/L) 4206±1801 4574±2050 0.384
Progesterone on the day of oocytes retrieval (nmol/L) 49.4±22.6 44.7±17.8 0.447
Number of obtained oocytes 21.3±8.8 18.8±6.6 0.095
ICSI 48/58 (82.8%) 44/53 (83.0%) 1
Number of oocytes with two pronuclei 2 10.2±5.9 9.3±4.8 0.550
Assisted hatching 49/58 (84.5%) 42/53 (79.2%) 0.622
Cancelled before ET 5/58 (8.6%) 6/53 (11.3%) 0.755
Number of patients with ET 53 47  
Number of transferred embryos – 1 7/53 (13.2%) 5/47 (10.6%) 0.54
Number of transferred embryos – 2 44/53 (83.0%) 42/47 (89.4%)
Number of transferred embryos – 3 2/53 (3.8%) 0/47 (0%)
Endometrium width ET (mm) 11.7±2.9 12.0±3.5 0.972
Estradiol on ET (pmol/L) 5675±3289 5131±2361 0.643
Progesterone on ET (nmol/L) 227.0±134.3 213.4±120.5 0.804
Number of cryopreserved embryos 3.2±4.3 2.2±3.0 0.488
Ovarian hyperstimulation syndrome 1st degree 2/53 (3.8%) 0/47 (0.0%) 0.142
Ovarian hyperstimulation syndrome 2nd degree 2/53 (3.8%) 2/47 (4.3%) 
Ovarian hyperstimulation syndrome 3rd degree 4/53 (7.5%) 0/47 (0.0%)
Estradiol on the day of positive hCG (pmol/L) 3712.0±5794.8 3588.1±5570.0 0.755
Progesterone on the day of positive hCG (nmol/L) 124.9±137.8 93.4±99.4 0.222
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The groups were compared using the Mann-Whitney 
U-test and exact Fisher test for qualitative markers. There 
were no significant differences between means for any of 
the variables (P>0.05).
Efficiency evaluation 
Efficiency, fertilization rate, implantation rate, preg-
nancy rate and take home baby rate were selected for 
evaluation in both groups. The groups were compared 
using the MW U-test and exact Fisher probability test.
There were no significant differences between 
(Table 2). 
Safety evaluation 
The safety of the two preparations was compared ac-
cording to the results of vaginal smear cultivation and 
signs of vaginal inflammation before and after treatment. 
There was no statistically significant differ before and af-
ter treatment (69.8% and 68.9% resp.).
Evaluation of tolerance
The tolerance of the preparations was evaluated using 
the 21 areas in the questionnaire. Crinone 8% exhibited 
less subjective complaints than Utrogestan. The evalua-
tion was carried out using a MW U-test (Table 3).
Table 2. Results for efficiency.
Parameter Utrogestan Crinone 8% P
Pregnancy based on a positive pregnancy blood test 36/53 (67.9%) 28/47 (59.6%) 0.411a
Number of pregnancies by US (number of gestation sacs before proved 
heart beat) - singletons 26/53 (49.1%) 18/47 (38.3%) 0.317a
Number of pregnancies by US (number of gestation sacs before proved 
heart beat) - twins 10/53 (18.9%) 10/47 (21.3%) 0.806a
Vital pregnancies (US proved heart beat) 29/53 (54.7%) 25/47 (53.2%) 1.000a
Vital pregnancies more than 12th week of gravidity 28/53 (52.8%) 22/47 (46.8%) 0.689a
Vital pregnancies more than 20th week of gravidity 28/53 (52.8%) 21/47 (44.7%) 0.431a
Births 28/53 (52.8%) 20/47 (42.6%) 0.324a
Number of delivered foetuses–singletons 19/53 (35.8%) 11/47 (23.4%) 0.196a
Number of delivered foetuses–twins 9/53 (17.0%) 9/47 (19.1%) 0.800a
Duration of pregnancies ( gest. weeks) 38.3±2.5 37.3±3.2 0.299b
Vaginal delivery 18/53 (34.0%) 7/47 (14.9%) 0.037a
Forceps delivery  0 0  
VEX delivery 1/53 (1.9%) 1/47 (2.1%) 1.000a
Cesarean section 9/53 (17.0%) 12/47 (25.5%) 0.333a
1st foetus – male 14/53 (26.4%) 15/47 (31.9%) 0.660a
1st foetus – female 14/53 (26.4%) 5/47 (10.6%) 0.072a
1st foetus birth weight 3179.2±771.0 2769.5±686.8 0.132b
1st foetus birth height 49.3±3.1 47.8±4.0 0.192b
2nd foetus – male 2/53 (3.8%) 3/47 (6.4%) 0.664a
2nd foetus – female 7/53 (13.2%) 6/53 (12.8%) 1.000a
2nd foetus birth weight 2335.0±416.6 2182.2±620.7 0.691b
2nd foetus birth height 45.7±3.3 45.6±4.1 0.893b
Fertilization rate 52.20% 50.20% 0.692b
Implantation rate 48.10% 41.50% 0.390b
Pregnancy rate 67.00% 57.00% 0.314b
Take home baby rate 52.80% 42.60% 0.485a
a The Fisher exact test) b The Mann-Whitney U-test
DISCUSSION
Luteal phase insufficiency after COH is due to the 
supraphysiological levels of stimulating hormones. Luteal 
support using hCG or P is therefore an essential part of 
the treatment in stimulated cycles. Micronized progester-
one (Utrogestan) enables better oral absorption. After 
oral administration, primary passage through the liver 
however leads to significant degradation of P. Therefore 
only 10% of bioactive substance remains in the circula-
tion. Increased orally administrated doses of P causes 
fatigue and somnolence in most patients4. However in-
creased oral doses of P do not lead to proper secretory 
transformation of the endometrium20. To overcome this 
setback, dydrogesterone (Duphaston) was introduced into 
the luteal support. This progestogene given orally has no 
estrogenic or androgenic effect and it ensures proper se-
cretory transformation of the endometrium. Even if the 
clinical findings of the luteal support with dydrogester-
one are comparable with the vaginal use of P, however 
dydrogesterone may cause, in some cases, non-adequate 
secretive transformation of endometrium21,22.
Intramuscular administration of P enables high effi-
ciency without the problems that may be encountered in 
oral administration. The usual dosage ranges between 25 – 
100 mg daily. The efficiency of intramuscular P has been 
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Table 3. Evaluation of tolerance in the group with Utrogestan and in the group with Crinone 8%.
Questions on problems connected with medication Utrogestan Crinone 8% P
Problems with vaginal administration of a medicament 1.2±0.6 1.0±0.1 0.023
Unpleasant feelings on insertion 1.3±0.6 1.1±0.3 0.47
Vaginal discharge 2.3±0.7 1.9±0.5 0.001
Feeling of discomfort- sickness 1.3±0.5 1.1±0.4 0.203
Vomiting 1.1±0.4 1.0±0.0 0.032
Constipation 1.3±0.8 1.3±0.6 0.546
Diarrhoea 1.3±0.7 1.0±0.1 0.022
Stomach-ache 1.3±0.6 1.2±0.6 0.154
Headache 1.3±0.6 1.2±0.5 0.368
Breast tension 1.7±0.7 1.9±0.7 0.18
Joint ache 1.1±0.5 1.1±0.2 0.803
Itching 1.4±0.6 1.1±0.3 0.028
Somnolence 1.9±0.8 1.6±0.7 0.058
Unpleasant feeling in the genitals area 1.2±0.6 1.3±0.5 0.804
Increased vaginal secretion 1.5±0.7 1.5±0.6 0.544
Irritation of external genitals by discharge 1.1±0.4 1.1±0.4 0.919
Urinary frequency during the day 1.8±0.7 1.6±0.6 0.378
Urinary frequency during the night 1.9±0.7 1.8±0.6 0.448
Decreased sexual desire 1.5±0.8 1.3±0.5 0.17
Dyspareunia 1.1±0.3 1.1±0.2 0.821
Spotting or bleeding after intercourse 1.3±0.7 1.4±0.8 0.211
confirmed and it is at least comparable or even better than 
vaginal administration23,24. However daily intramuscular 
injections are annoying. There may also be side effects 
like allergic reactions or sterile abscesses25. Eosinophilic 
pneumonia in an otherwise healthy patient has even been 
reported26. For these rteasons, intramuscular P is not rec-
ommended as the method of the first choice for luteal 
support21.
Vaginal P enables direct transfer of P from vagina into 
the uterus. It bypasses liver metabolism27. High levels of P 
in the uterus and low levels in the serum were explained 
by the theory of a reverse flow interchangeable mecha-
nism between the vagina and the uterus28. 
There are two available preparations of micronized 
P for vaginal use (Utrogestan, Crinone 8%). Utrogestan 
(Laboratoires Besins Iscovesco, Paris, France) is recom-
mnded for luteal support via the vagina even though it was 
originally designed for oral use. The usual dose is 600- 
800 mg given 3 times daily. Crinone 8% gel is a jelly with 
micronized progesterone (Merck Serono Ltd, Feltham, 
UK) specifically designed for vaginal use. Vaginal admin-
istration (90 mg/day) provides several advantages and the 
efficiency is at least the same as the intramuscular one23. 
It is more convenient for patients and allergic reactions 
are rare. Comparing Utrogestan and Crinone 8%, there 
were no differences in efficiency though patients prefer 
Crinone 8% for better tolerance29,30. For luteal support, 
vaginal P is therefore the first method of choice. It is 
also possible to stimulate corpora lutea by the means of 
hCG like induction of LH peak for final maturation of 
the oocytes. It is however limited due to the risk of OHSS 
(ref.31). Another type of hCG (human and recombinant) 
can be administrated intramuscularly or subcutaneously11. 
But intramuscular hCG is preferred11. In 2005, GnRh was 
introduced as a new option for luteal support. It was ex-
pected that GnRh agonists could restore LH levels during 
the luteal phase and thereby ensure sufficient transforma-
tion of the endometrium11. In 2004 Tesarik suggested, 
within a program of donated oocytes, to give GnRh ago-
nists after ICSI for 6 days. The efficiency of this method 
was proved by increased implantation and birth rate32. It 
was also recommended to administer P and E orally as a 
support of the luteal phase. The efficiency of P in luteal 
support has been confirmed but not E. Farhi proved that 
addition of E could be beneficial after the COH in long 
protocols with GnRH-a but a meta-analysis from 2008 
showed that addition of E to  P for the luteal support did 
not improve the results33,34. There is no generally accepted 
consensus about the length of luteal support after the 
COH. A study from 2002 evaluated, whether the extended 
luteal support in an early pregnancy had any impact on 
pregnancy results. The data confirmed that the luteal sup-
port could be efficient until the positivity of hCG but its 
later prolongation has no positive effect on abortion rate 
or number of deliveries35. The administration of P in an 
early pregnancy only postpones the date of abortions but 
does not increase the live born baby ratio36. Despite these 
facts luteal support is routinely given from day 10 up to 
the 12th week of pregnancy24. Micronized progesterone 
given orally has limited efficiency. Administration of P 
by the vagina is preferred.
CONCLUSIONS
Utrogestan and Crinone 8% were compared as a means 
of a luteal support in the IVF/ET program in this study. 
There were no statistically significant differences between 
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the two drugs in terms of efficiency or safety.  Crinone 
8% was more comfortable for patients. As luteal support 
is an essential part of current IVF/ICSI-ET programs, the 
study outcomes suggest that the micronized progesterone 
vaginal gel is the best way. 
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